CyBorD Plus Daratumumab

A Phase II Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Patients With Monoclonal Gammopathy of Renal Significance (MGRS)

What's the purpose of the trial?

The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma.

Trial status

Accepting patients

Phase
Phase 2
Enrollment
53
Last Updated
2 weeks ago
Am I Eligible

Participating Centers

There are 4 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Bortezomib
  • Cyclophosphamide
  • Daratumumab
  • Dexamethasone

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Patients with Cast Nephropathy

Accepting patients

Patients with Other MGRS Associated Diseases

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.